Gefurulimab
Sponsors
Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.
Conditions
Generalized Myasthenia GravisGeneralized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)HealthygMG
Phase 1
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Active, not recruitingCTIS2023-508284-77-00
Start: 2022-11-16Target: 82Updated: 2025-11-17
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RecruitingNCT06607627
Start: 2024-11-13End: 2029-01-23Target: 12Updated: 2026-04-01
An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)
RecruitingCTIS2024-515157-17-00
Start: 2025-12-22Target: 4Updated: 2025-03-24